Clinical Trial Update: A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX SC in adults with obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• ISIS-FGFR4RX SC (ISIS-FGFR4RX)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Obesity | Phase 2 | Status: COMPLETED